Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AMGN Stock Forecast 2026-2027
$349.39
Current Price
$188.34B
Market Cap
Buy 13
Hold 18
Sell 3
Wall St Analyst Ratings
Distance to AMGN Price Targets
+23.6%
To High Target of $432.00
+0.5%
To Median Target of $351.00
-42.8%
To Low Target of $200.00
AMGN Price Momentum
-0.5%
1 Week Change
-0.6%
1 Month Change
+26.0%
1 Year Change
+6.7%
Year-to-Date Change
-10.7%
From 52W High of $391.29
+33.6%
From 52W Low of $261.43
📊 TOP ANALYST CALLS
Did AMGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Amgen is one of their latest high-conviction picks.
Latest AMGN Stock Price Targets & Analyst Predictions
Based on our analysis of 45 Wall Street analysts, AMGN has a neutral consensus with a median price target of $351.00 (ranging from $200.00 to $432.00). The overall analyst rating is Buy (7.0/10). Currently trading at $349.39, the median forecast implies a 0.5% upside. This outlook is supported by 13 Buy, 18 Hold, and 3 Sell ratings.
The most optimistic forecast comes from David Amsellem at Piper Sandler, projecting a 23.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMGN Analyst Ratings
13
Buy
18
Hold
3
Sell
AMGN Price Target Range
Low
$200.00
Average
$351.00
High
$432.00
Current: $349.39
Latest AMGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 13, 2026 | UBS | Michael Yee | Buy | Maintains | $400.00 |
| Apr 10, 2026 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $326.00 |
| Apr 9, 2026 | Guggenheim | Vamil Divan | Neutral | Maintains | $351.00 |
| Apr 8, 2026 | Cantor Fitzgerald | Carter Gould | Neutral | Reiterates | $350.00 |
| Mar 10, 2026 | Jefferies | Akash Tewari | Hold | Initiates | $350.00 |
| Feb 20, 2026 | Barclays | Emily Field | Equal-Weight | Initiates | $350.00 |
| Feb 19, 2026 | Wells Fargo | Mohit Bansal | Equal-Weight | Maintains | $375.00 |
| Feb 18, 2026 | Piper Sandler | David Amsellem | Overweight | Maintains | $432.00 |
| Feb 12, 2026 | Freedom Broker | Hold | Downgrade | $N/A | |
| Feb 6, 2026 | Argus Research | Jasper Hellweg | Buy | Maintains | $400.00 |
| Feb 6, 2026 | Guggenheim | Vamil Divan | Neutral | Maintains | $347.00 |
| Feb 4, 2026 | Leerink Partners | David Risinger | Outperform | Maintains | $355.00 |
| Feb 4, 2026 | Cantor Fitzgerald | Carter Gould | Neutral | Maintains | $350.00 |
| Feb 4, 2026 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $309.00 |
| Feb 4, 2026 | Citigroup | Geoff Meacham | Neutral | Maintains | $345.00 |
| Jan 26, 2026 | UBS | Michael Yee | Buy | Maintains | $390.00 |
| Jan 20, 2026 | Bernstein | Courtney Breen | Market Perform | Downgrade | $335.00 |
| Jan 8, 2026 | Truist Securities | Gregory Renza | Hold | Maintains | $319.00 |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Assumes | $380.00 |
| Dec 12, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $304.00 |
Amgen Inc. (AMGN) Competitors
The following stocks are similar to Amgen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Amgen Inc. (AMGN) Financial Data
Amgen Inc. has a market capitalization of $188.34B with a P/E ratio of 24.5x. The company generates $36.75B in trailing twelve-month revenue with a 21.0% profit margin.
Revenue growth is +8.6% quarter-over-quarter, while maintaining an operating margin of +30.5% and return on equity of +106.1%.
Valuation Metrics
Market Cap
$188.34B
Enterprise Value
$234.02B
P/E Ratio
24.5x
PEG Ratio
0.2x
Price/Sales
5.1x
Growth & Margins
Revenue Growth (YoY)
+8.6%
Gross Margin
+69.8%
Operating Margin
+30.5%
Net Margin
+21.0%
EPS Growth
+112.6%
Financial Health
Cash/Price Ratio
+4.8%
Current Ratio
1.1x
Debt/Equity
640.3x
ROE
+106.1%
ROA
+7.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Amgen Inc. (AMGN) Business Model
About Amgen Inc.
What They Do
Biotechnology company delivering human therapeutics globally.
Business Model
Amgen develops and markets a range of biopharmaceutical products targeting serious health conditions. The company generates revenue through the sales of its innovative therapeutics, which include treatments for diseases such as rheumatoid arthritis, osteoporosis, cancer, and cardiovascular issues, among others.
Additional Information
Founded in 1980 and headquartered in Thousand Oaks, California, Amgen employs approximately 28,000 people. The company is recognized for its significant contributions to global healthcare advancements, particularly in oncology, inflammation, and rare disorders.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
31,500
CEO
Mr. Robert A. Bradway
Country
United States
IPO Year
1984
Website
www.amgen.comAmgen Inc. (AMGN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
J&J Beats Q1 Earnings & Sales Estimates, Raises 2026 Outlook
JNJ tops Q1 earnings and sales estimates, lifts 2026 outlook as strong oncology and MedTech growth offset steep Stelara decline.
Apr 14, 2026
By Zacks Equity Research
Analyst Blog
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Apr 10, 2026
By Zacks Equity Research
Tale of the Tape
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
Amgen (AMGN) closed at $355.6 in the latest trading session, marking a +1.66% move from the prior day.
Apr 09, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Amgen's lung cancer drug tarlatamab received approval from China's National Medical Products Administration, as announced by partner BeOne Medicines.
Why It Matters
Amgen's lung cancer drug tarlatamab gaining approval in China expands market potential, potentially boosting revenue and market share, impacting stock performance positively.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Amgen (AMGN) has a strong earnings surprise history and is well-positioned for a potential beat in its upcoming quarterly report.
Why It Matters
Amgen's strong earnings surprise history and favorable conditions suggest potential upside in its upcoming report, indicating possible stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Amgen (AMGN) is currently attracting significant interest from Zacks.com users, highlighting potential factors that may influence its stock performance.
Why It Matters
Increased attention on Amgen suggests heightened investor interest, potentially influencing stock performance and market sentiment. Monitoring developments could lead to trading opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Amgen's subcutaneous Tepezza has achieved phase III trial goals for thyroid eye disease, matching IV efficacy while offering faster dosing, potentially increasing access.
Why It Matters
Amgen's Tepezza achieving phase III goals and offering faster dosing could enhance market share in thyroid eye disease, potentially driving revenue growth and increasing investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Here's Why Amgen (AMGN) is a Strong Value Stock
10 days ago
Quick Summary
Zacks Style Scores help investors identify top-rated stocks aligned with their investing style, providing a useful tool for stock selection.
Why It Matters
The Zacks Style Scores help identify high-potential stocks aligned with specific investing strategies, aiding informed decision-making and potentially enhancing portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Amgen (AMGN) and BioAge Labs, Inc. (BIOA) have been compared to their sector performance for the year to date. Specific performance metrics were not provided in the excerpt.
Why It Matters
Performance comparisons indicate how well Amgen and BioAge Labs are faring against their peers, influencing investor sentiment and potential stock movements in the biotech sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About AMGN Stock
What is Amgen Inc.'s (AMGN) stock forecast for 2026?
Based on our analysis of 45 Wall Street analysts, Amgen Inc. (AMGN) has a median price target of $351.00. The highest price target is $432.00 and the lowest is $200.00.
Is AMGN stock a good investment in 2026?
According to current analyst ratings, AMGN has 13 Buy ratings, 18 Hold ratings, and 3 Sell ratings. The stock is currently trading at $349.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AMGN stock?
Wall Street analysts predict AMGN stock could reach $351.00 in the next 12 months. This represents a 0.5% increase from the current price of $349.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Amgen Inc.'s business model?
Amgen develops and markets a range of biopharmaceutical products targeting serious health conditions. The company generates revenue through the sales of its innovative therapeutics, which include treatments for diseases such as rheumatoid arthritis, osteoporosis, cancer, and cardiovascular issues, among others.
What is the highest forecasted price for AMGN Amgen Inc.?
The highest price target for AMGN is $432.00 from David Amsellem at Piper Sandler, which represents a 23.6% increase from the current price of $349.39.
What is the lowest forecasted price for AMGN Amgen Inc.?
Price targets from Wall Street analysts for AMGN are not currently available. The stock is trading at $349.39.
What is the overall AMGN consensus from analysts for Amgen Inc.?
The overall analyst consensus for AMGN is neutral. Out of 45 Wall Street analysts, 13 rate it as Buy, 18 as Hold, and 3 as Sell, with a median price target of $351.00.
How accurate are AMGN stock price projections?
Stock price projections, including those for Amgen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 3:13 PM UTC